465 related articles for article (PubMed ID: 18854720)
1. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Int Clin Psychopharmacol; 2008 Nov; 23(6):325-31. PubMed ID: 18854720
[TBL] [Abstract][Full Text] [Related]
2. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
4. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.
Lasser RA; Bossie CA; Zhu Y; Locklear JC; Kane JM
Ann Clin Psychiatry; 2007; 19(2):65-71. PubMed ID: 17612845
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone.
Martin SD; Libretto SE; Pratt DJ; Brewin JS; Huq ZU; Saleh BT
Curr Med Res Opin; 2003; 19(4):298-305. PubMed ID: 12841922
[TBL] [Abstract][Full Text] [Related]
6. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.
Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R
Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649
[TBL] [Abstract][Full Text] [Related]
7. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable.
Gharabawi G; Bossie C; Turkoz I; Kujawa M; Mahmoud R; Simpson G
J Nerv Ment Dis; 2007 Dec; 195(12):976-82. PubMed ID: 18091190
[TBL] [Abstract][Full Text] [Related]
8. Direct transition to long-acting risperidone--analysis of long-term efficacy.
Kissling W; Heres S; Lloyd K; Sacchetti E; Bouhours P; Medori R; Llorca PM
J Psychopharmacol; 2005 Sep; 19(5 Suppl):15-21. PubMed ID: 16144782
[TBL] [Abstract][Full Text] [Related]
9. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.
Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W
J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781
[TBL] [Abstract][Full Text] [Related]
10. Clinical review of a long-acting, injectable formulation of risperidone.
Knox ED; Stimmel GL
Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting.
Kim B; Lee SH; Choi TK; Suh S; Kim YW; Lee E; Yook KH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1231-5. PubMed ID: 18442879
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
Lasser RA; Bossie CA; Zhu Y; Gharabawi G; Eerdekens M; Davidson M
Int J Geriatr Psychiatry; 2004 Sep; 19(9):898-905. PubMed ID: 15352149
[TBL] [Abstract][Full Text] [Related]
13. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
[TBL] [Abstract][Full Text] [Related]
14. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
15. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].
Faludi G
Neuropsychopharmacol Hung; 2005 Mar; 7(1):22-7. PubMed ID: 16167464
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience and management considerations with long-acting risperidone.
Parellada E
Curr Med Res Opin; 2006 Feb; 22(2):241-55. PubMed ID: 16466596
[TBL] [Abstract][Full Text] [Related]
17. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
18. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
Chue P; Eerdekens M; Augustyns I; Lachaux B; Molcan P; Eriksson L; Pretorius H; David AS
Eur Neuropsychopharmacol; 2005 Jan; 15(1):111-7. PubMed ID: 15572280
[TBL] [Abstract][Full Text] [Related]
20. [Maintenance pharmacotherapy of schizophrenia: remission and the effectiveness of long-acting risperidone therapy].
Sárosi A
Neuropsychopharmacol Hung; 2006 Dec; 8(4):179-87. PubMed ID: 17211053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]